Intelligence Feed event · Equity · 2026-09-19

    Twist Bioscience partners with Eli Lilly on TuneLab AI discovery

    Question

    Twist Bioscience partners with Eli Lilly on TuneLab AI discovery

    Direct answer

    Twist Bioscience announced an agreement with Eli Lilly to provide antibody characterization data for the Lilly TuneLab platform. Twist will deploy its AbLab screening technology to support AI-driven antibody drug discovery programs. The agreement provides fee-for-service data generation revenue for Twist while providing Eli Lilly with scaled experimental validation datasets.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Twist Bioscience partners with Eli Lilly on TuneLab AI discovery”, revision 1, evidence through 2026-09-19. https://marketontology.com/market-events/2026-09-19/twist-bioscience-partners-with-eli-lilly-on-tunelab-ai-discovery-029da5

    EQUITY
    Twist Bioscience partners with Eli Lilly on TuneLab AI discovery
    Twist Bioscience announced an agreement with Eli Lilly to provide antibody characterization data for the Lilly TuneLab platform. Twist will deploy its AbLab screening technology to support AI-driven antibody drug discovery programs. The agreement provides fee-for-service data generation revenue for Twist while providing Eli Lilly with scaled experimental validation datasets.
    TWSTLLY
    Impact
    69
    SEP 19
    SIG
    88%
    TWSTLLY
    Twist Bioscience partners with Eli Lilly on TuneLab AI discovery
    Twist Bioscience announced an agreement with Eli Lilly to provide antibody characterization data for the Lilly TuneLab platform. Twist will deploy its AbLab screening technology to support AI-driven antibody drug discovery programs. The agreement provides fee-for-service data generation revenue for Twist while providing Eli Lilly with scaled experimental validation datasets.
    → Collaboration agreements with large-cap pharmaceutical sponsors generate antibody screening revenue and validate AI platform monetization.
    Impact
    Twist Bioscience announced an agreement with Eli Lilly to provide antibody characterization data for the Lilly TuneLab platform. Twist will deploy its AbLab screening technology to support AI-driven antibody drug discovery programs. The agreement provides fee-for-service data generation revenue for Twist while providing Eli Lilly with scaled experimental validation datasets.
    Affected
    TWSTLLY
    Transmission
    Collaboration agreements with large-cap pharmaceutical sponsors generate antibody screening revenue and validate AI platform monetization.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TWSTbiotech AI discovery services revenue expansionUp1-4wTwist partnered with Eli Lilly on TuneLab AI antibody discovery.
    LLYcomputational drug pipeline candidate generationWatch1-3mEli Lilly integrates Twist's AbLab characterization data into TuneLab.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month